History
Key milestones in TheraNovis's journey
2025
2 eventsLaunch of semi-automated staining system
Secured KRW 220M in funding from a private investment fundKRW 0M
2024
6 eventsMOU signed with AtheonBio
MOU signed with Intec Scientific
Selected for MOTIE Materials & Components Technology Development Program (KRW 10B / 5 years)KRW 0M
Initiated establishment of Boston, USA liaison office
Secured KRW 1B in strategic (SI) investment from IntekPlusKRW 0M
Launch of Skin GeneCurator skin condition assessment service
2023
6 eventsSecured KRW 300M in TIPS fundingKRW 0M
Secured KRW 336M in strategic (SI) investmentKRW 0M
Selected for MSS Deep-Tech TIPS Program (KRW 1.5B / 3 years)KRW 0M
Selected for Seoul-type TIPS Program (KRW 400M / 2 years)KRW 0M
Selected for Medical Device Industry Transition Infrastructure Program
Launch of Phenoview (now AstraTSA)
2022
4 eventsExecuting the Regional Specialized Industry Development Program (MSS)
Selected for PNU Yangsan Bio Core Facility Program (KRW 600M / 3 years)KRW 0M
Selected for the KIBO Tech-Bridge Program
Selected for the Asan Medical Center Incentive Program
2021
3 eventsTheraNovis Co., Ltd. Established
MOU Signed with BioActs and Six Additional Organizations
Established Corporate R&D Centers (Hanam / Yangsan)
TheraNovis continues evolving into a global diagnostic platform company.